Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 1015-1022

  Teixeira, Sarah Fernandes ^a   Alexandre de Azevedo, Ricardo ^a   Salomon, Maria Alejandra Clavijo ^a   Jorge, Salomão Dória ^a   Levy, Débora ^a   Bydlowski, Sérgio Paulo ^a   Rodrigues, Cecília Pessoa ^a   Pizzo, Célia Regina ^a   Barbuto, José Alexandre Marzagão ^a   Ferreira, Adilson Kleber ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti proliferative; Apoptosis; BFD 22; Furoxan; Lung cancer; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOFUROXAN; BENZOXAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB;

ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; LUNG NEOPLASMS; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BENZOXAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84916233817     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.09.007     Document Type: Article

References (34)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Travis W.D., Brambilla E., Riely G.J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 31:992-1001.
4. Vansteenkiste J., De Ruysscher D., Eberhardt W.E., Lim E., Senan S., Felip E., et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl 6):vi89-vi98.
5. Society A.C. Cancer facts and figures 2014 2014, Society A.C., Atlanta.
6. Cerecetto H., Porcal W. Pharmacological properties of furoxans and benzofuroxans: recent developments. Mini Rev Med Chem 2005, 5:57-71.
7. Sartini S., Cosconati S., Marinelli L., Barresi E., Di Maro S., Simorini F., et al. Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies. J Med Chem 2012, 55:10523-10531.
8. Schiefer I.T., VandeVrede L., Fa' M., Arancio O., Thatcher G.R. Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents. J Med Chem 2012, 55:3076-3087.
9. Aguirre G., Boiani L., Boiani M., Cerecetto H., Di Maio R., González M., et al. New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: quantitative structure-activity relationship studies. Bioorg Med Chem 2005, 13:6336-6346.
10. Castro J.A., de Mecca M.M., Bartel L.C. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006, 25:471-479.
11. Cabrera M., Lavaggi M.L., Hernández P., Merlino A., Gerpe A., Porcal W., et al. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicol Lett 2009, 190:140-149.
12. Jorge S.D., Ishii M., Palace-Berl F., Ferreira A.K., Sá Júnior P.L., de Oliveira A.A., et al. Preliminaryin vitro evaluation of N'-(benzofuroxan-5-yl)methylene benzohydrazide derivatives as potential anti-Trypanosoma cruziagents. MedChemComm 2012, 824-828. European Federation for Medicinal Chemistry, Harvard University, USA.
13. Fairlamb A.H., Cerami A. Metabolism and functions of trypanothione in the kinetoplastida. Annu Rev Microbiol 1992, 46:695-729.
14. Krauth-Siegel R.L., Meiering S.K., Schmidt H. The parasite-specific trypanothione metabolism of trypanosoma and leishmania. Biol Chem 2003, 384:539-549.
15. Holloway G.A., Charman W.N., Fairlamb A.H., Brun R., Kaiser M., Kostewicz E., et al. Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity. Antimicrob Agents Chemother 2009, 53:2824-2833.
16. Jorge S.D., Palace-Berl F., Mesquita Pasqualoto K.F., Ishii M., Ferreira A.K., Berra C.M., et al. Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents. Eur J Med Chem 2013, 64:200-214.
17. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
18. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
19. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
20. Paz-Ares L.G., Biesma B., Heigener D., von Pawel J., Eisen T., Bennouna J., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012, 30:3084-3092.
21. Zhang J., Gold K.A., Kim E. Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs 2012, 21:1417-1426.
22. Ghosh P., Ternai B., Whitehouse M. Benzofurazans and benzofuroxans: biochemical and pharmacological properties. Med Res Rev 1981, 1:159-187.
23. Montanaro G., Bertinaria M., Rolando B., Fruttero R., Lucas C.D., Dorward D.A., et al. Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. Bioorg Med Chem 2013, 21:2107-2116.
24. Han C., Huang Z., Zheng C., Wan L., Zhang L., Peng S., et al. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. J Med Chem 2013, 56:4738-4748.
25. Capdevila J., Iglesias L., Halperin I., Segura A., Martínez-Trufero J., Vaz M., et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012, 19:209-216.
26. Larkin J., Paine A., Tumur I., Cappelleri J.C., Healey P.J., Foley G., et al. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 2013, 14:27-39.
27. Gollob J.A., Rathmell W.K., Richmond T.M., Marino C.B., Miller E.K., Grigson G., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007, 25:3288-3295.
28. Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53:917-930.
29. Brose M.S., Nutting C.M., Sherman S.I., Shong Y.K., Smit J.W., Reike G., et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011, 11:349.
30. de Wilt L.H., Kroon J., Jansen G., de Jong S., Peters G.J., Kruyt F.A. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?. Crit Rev Oncol Hematol 2013, 85:363-372.
31. Pore M.M., Hiltermann T.J., Kruyt F.A. Targeting apoptosis pathways in lung cancer. Cancer Lett 2013, 332:359-368.
32. Stegehuis J.H., de Wilt L.H., de Vries E.G., Groen H.J., de Jong S., Kruyt F.A. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 2010, 13:2-15.
33. Azijli K., Yuvaraj S., van Roosmalen I., Flach K., Giovannetti E., Peters G.J., et al. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis 2013, 18:851-860.
34. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993, 9:541-573.